TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28464042

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd for six months (long-term)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd for six months (short-course)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd for six months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 56
Study: 26639505

Group type: EXPERIMENTAL
Intervention: D-Worm (herbal medicine)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Mebandazole (allopathic drug)
Number of subjects: 190
Study: 23760288

Group type: EXPERIMENTAL
Intervention: RAS blockade
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16487437

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 2

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 2
Study: 14530608

Group type: EXPERIMENTAL
Intervention: Low-dose ACTH test (LDAT) 0.5 microg/m2
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Standard-dose ACTH test (SDAT) 250 microg/m2
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-dose ACTH test (LDAT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Standard-dose ACTH test (SDAT)
Number of subjects: 29
Study: 10333674

Group type: EXPERIMENTAL
Intervention: Acute inpatient geriatrics unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 8955660

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 27
Study: 1896702

Group type: EXPERIMENTAL
Intervention: Calcium alginate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Telfa
Number of subjects: 82
Study: 6819275

Group type: EXPERIMENTAL
Intervention: Neutron therapy (20 daily fractions over four weeks)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Photon therapy (20 daily fractions over four weeks)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 192
Study: 31932116

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 28365896

Group type: EXPERIMENTAL
Intervention: Voice rehabilitation (VR)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 25054347

Group type: EXPERIMENTAL
Intervention: Scapular mobilization
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham scapular mobilization
Number of subjects: 66

Group type: COMPARATOR
Intervention: Supervised exercise
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 66
Study: 24427694

Group type: EXPERIMENTAL
Intervention: Esmolol (group ESM, n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nitroglycerine (NTG, group NTG, n = 26)
Number of subjects: 52
Study: 21525191

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D (CaD) supplements: 500 mg calcium carbonate plus 200 IU vitamin D(3) twice daily (1000 mg and 400 IU daily, respectively) for an average of 7.0 years.
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo group for an average of 7.0 years.
Number of subjects: 36282
Study: 18647282

Group type: EXPERIMENTAL
Intervention: Dual-mechanism coating comprising pH-responsive enteric polymer (Eudragit S) and biodegradable polysaccharide (resistant starch)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control conditions: (i) without food, (ii) with breakfast, (iii) 30 min before breakfast
Number of subjects: 8
Study: 16633226

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 61

Group type: COMPARATOR
Intervention: Latanoprost (control)
Number of subjects: 61
Study: 14694836

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study: 10840538

Group type: EXPERIMENTAL
Intervention: Remifentanil/Propofol (R/P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane/Fentanyl (S/F)
Number of subjects: 60
Study: 8814649

Group type: EXPERIMENTAL
Intervention: Ethanol (0.55 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol (0.55 g/kg) with deviant tones
Number of subjects: 10
Study: 1325036

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g once orally)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Doxycycline (100 mg orally twice daily for seven days)
Number of subjects: 457
Study: 6677078

Group type: EXPERIMENTAL
Intervention: Cognitive urge control maintenance condition
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Abstainers
Number of subjects: 94

Group type: COMPARATOR
Intervention: Relapsers
Number of subjects: 94
Study: 31441430

Group type: EXPERIMENTAL
Intervention: Health Records on iPhone
Number of subjects: 0
Study: 30266729

Group type: EXPERIMENTAL
Intervention: High dose RS2 (48 g daily for 2 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low dose RS2 (3 g/2,500 kcal daily for 2 weeks)
Number of subjects: 12
Study: 26691409

Group type: EXPERIMENTAL
Intervention: Hypoxia Level 2 (HH, FiO2 = 12.6%)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hypoxia Level 1 (HL, FiO2 = 16%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normoxia (NR, FiO2 = 21%)
Number of subjects: 25
Study: 25178924

Group type: EXPERIMENTAL
Intervention: O₃ (0.300 ppm) + DE (300 μg/m³)
Number of subjects: 15

Group type: COMPARATOR
Intervention: O₃ (0.300 ppm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DE (300 μg/m³)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: O₃ (0.300 ppm) after DE exposure
Number of subjects: 15
Study: 21942262

Group type: COMPARATOR
Intervention: bupropion (300 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: varenicline (2 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 58
Study: 19623601

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 6 weeks, then 10 mg/day thereafter
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Donepezil initiated during the extension study
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 885
Study: 17305413

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium 12.5mg tablets
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diclofenac potassium 25mg (2 tablets)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diclofenac potassium (up to 75mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diclofenac potassium and ibuprofen
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diclofenac potassium
Number of subjects: 13
Study: 15863458

Group type: EXPERIMENTAL
Intervention: Mitral tetrahedron (MT) assessment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Scoring system employing parameters of the whole MT
Number of subjects: 58
Study: 12066736

Group type: EXPERIMENTAL
Intervention: Topical 4% amethocaine gel (Ametop)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine infiltration
Number of subjects: 100
Study: 10223780

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg to 20 mg for 8 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8665994

Group type: EXPERIMENTAL
Intervention: 0.1 mg suriclone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2 mg suriclone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.4 mg suriclone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2193503

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meals
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meals
Number of subjects: 7

Group type: COMPARATOR
Intervention: Fasting (15-24 h)
Number of subjects: 7
Study: 486351

Group type: EXPERIMENTAL
Intervention: A‐type therapists with schizophrenics
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: A‐type therapists with non‐schizophrenics
Number of subjects: 235

Group type: COMPARATOR
Intervention: Short hospitalization
Number of subjects: 235

Group type: COMPARATOR
Intervention: Long hospitalization
Number of subjects: 235
Study: 31323594

Group type: EXPERIMENTAL
Intervention: rTMS on left inferior parietal lobe (rTMS‐lIPL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: rTMS on left dorsolateral prefrontal cortex (rTMS‐lDLPFC; control condition)
Number of subjects: 20
Study: 28659133

Group type: EXPERIMENTAL
Intervention: Study mouthwash A
Number of subjects: 504

Group type: COMPARATOR
Intervention: Study mouthwash B
Number of subjects: 504
Study: 26307376

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 2876

Group type: COMPARATOR
Intervention: No IPC (Control)
Number of subjects: 2876
Study: 23342332

Group type: EXPERIMENTAL
Intervention: Glycine-based airflow system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hand instrumentation with Teflon curettes
Number of subjects: 15
Study: 21289263

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) (2500 kJ/d)
Number of subjects: 35
Study: 19178124

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDT) with peripheral blood stem cell transplant (PBSCT) support
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard chemotherapy regimen (CHOP)
Number of subjects: 197
Study: 16904589

Group type: EXPERIMENTAL
Intervention: Postoperative intra-articular suction drain
Number of subjects: 118

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 118
Study: 15388963

Group type: EXPERIMENTAL
Intervention: Difructose anhydride III (DFAIII)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Palatinose
Number of subjects: 13
Study: 11245649

Group type: EXPERIMENTAL
Intervention: Activation mapping technique
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: On-site atrial potential analysis
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both methods combined
Number of subjects: 76
Study: 9413023

Group type: EXPERIMENTAL
Intervention: GHB (gammahydroxy butyric acid) at a dose of 25 mg/kg body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8877214

Group type: EXPERIMENTAL
Intervention: Tampon pharyngeal packing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gauze pharyngeal packing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no packing)
Number of subjects: 120
Study: 3464742

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stomatognathic treatment
Number of subjects: 50
Study: 31292752

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vegetarian Diet (VD)
Number of subjects: 23
Study: 30134956

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 76

Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 76
Study: 27173471

Group type: EXPERIMENTAL
Intervention: Cold-exposure (1 hour/day for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (avoiding cold exposure for 6 weeks)
Number of subjects: 28
Study: 24948347

Group type: EXPERIMENTAL
Intervention: Delayed-release cysteamine bitartrate (DR-CYS)
Number of subjects: 40
Study: 22399575

Group type: EXPERIMENTAL
Intervention: Exercise with TENS device
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise with cryotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 30
Study: 20423222

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine (11.86 mg or 5.93 mg of tocopherol)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Both AS03-adjuvanted and nonadjuvanted vaccines
Number of subjects: 680
Study: 19002338

Group type: COMPARATOR
Intervention: Sunscreen with very high protection level against UVB and UVA (containing Tinosorb M, Tinosorb S, and butyl methoxydibenzoylmethane) applied to the left dorsal forearm.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo applied to the right dorsal forearm.
Number of subjects: 12
Study: 15933483

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 11784224

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (HR per 10 mm Hg increase)
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: Regular smoking
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: High daily alcohol intake
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: Uric acid (HR per 1 mmol/L increase)
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: Physical inactivity during leisure time
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol level
Number of subjects: 6166
Study: 10362188

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Low-dose argatroban
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: High-dose argatroban
Number of subjects: 125
Study: 7726441

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study: 2187701

Group type: EXPERIMENTAL
Intervention: Dilevalol 100 mg once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carteolol 10 mg once daily
Number of subjects: 10
Study: 7243513

Group type: EXPERIMENTAL
Intervention: Moved to cribs from heated incubators (Group A: 1,600-1,700 gm; Group B: 1,800-1,900 gm)
Number of subjects: 14
Study: 6500777

Group type: EXPERIMENTAL
Intervention: Vincamine teprosilate (Teproside) administered intravenously (i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo administered intravenously (i.v.)
Number of subjects: 10
Study: 30696387

Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training (high-LT; 70-85% of maximum predicted heart rate; n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-intensity locomotor training (low-LT; 50-65% of maximum predicted heart rate; n=7)
Number of subjects: 13
Study: 29596044

Group type: EXPERIMENTAL
Intervention: High-Protein meal (HP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-Monounsaturated Fat meal (HMF)
Number of subjects: 24
Study: 27310969

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) at 5 mg/kg administered at weeks 0, 2, 6, and every 8 weeks thereafter until week 46; dose increased to 10 mg/kg for inadequate responders after week 30
Number of subjects: 18
Study: 24047799

Group type: EXPERIMENTAL
Intervention: Rotarix vaccine
Number of subjects: 102074

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102074
Study: 22677811

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.3 mg/kg, max. 15 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50% Nitrous oxide (N(2)O)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10% Nitrous oxide (N(2)O)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no sedation)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Growth-retarded children
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Very low dose of N(2)O (10%)
Number of subjects: 90
Study: 20211292

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18206

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18206
Study: 18798399

Group type: EXPERIMENTAL
Intervention: Misgav‐Ladach technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional cesarean section
Number of subjects: 48
Study: 16103236

Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: BQ‐123 (ET-1 receptor blockade)
Number of subjects: 11
Study: 11818934

Group type: EXPERIMENTAL
Intervention: New mechanical puncture echoendoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard linear echoendoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional radial scanning echoendoscope
Number of subjects: 20
Study: 10853111

Group type: EXPERIMENTAL
Intervention: High stimulation of the vagus nerve (VNS) during the E05 trial
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High stimulation of the vagus nerve (VNS) during the XE5 trial
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Last visit carried forward analysis for VNS
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Adverse events and physiological variables monitoring
Number of subjects: 199
Study: 8543520

Group type: EXPERIMENTAL
Intervention: Parent- and child-administered structured DSM-III-R DISC interviews
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Parents' and children's symptom checklist ratings
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Parents' ratings of their own symptoms
Number of subjects: 294
Study: 2407889

Group type: EXPERIMENTAL
Intervention: Polysulfone membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEAE-substituted cellulose membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellulose membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All membranes
Number of subjects: 0
Study: 7413152

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Cystoid macular edema patients
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Other patients (without cystoid macular edema)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (unilaterally aphakic eyes)
Number of subjects: 264
Study: 30566363

Group type: EXPERIMENTAL
Intervention: Probiotics (2.5 × 10^9 CFU/g) containing 9 bacterial strains (Ecologic Barrier)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 41
Study: 29737292

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified, likely placebo or standard treatment)
Number of subjects: 0
Study: 26474430

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-300 mg twice a day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 64
Study: 23388562

Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX) 50 mg/m/wk with temozolomide 75 mg/m and radiation 2.0 Gy, 5 d/wk for a total dose of 60 Gy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Temozolomide/radiation
Number of subjects: 25
Study: 22378262

Group type: EXPERIMENTAL
Intervention: Tafamidis (Vyndaqel; Pfizer)
Number of subjects: 0
Study: 19496531

Group type: EXPERIMENTAL
Intervention: Xenogeneic (mouse) gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Human gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both interventions (xenogeneic and human gp100)
Number of subjects: 19
Study: 17218661

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Quadruple-strand semitendinosus/gracilis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 99
Study: 15831193

Group type: EXPERIMENTAL
Intervention: Community intervention trial
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation research
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Outcome data-monitoring committee
Number of subjects: 8
Study: 11320362

Group type: EXPERIMENTAL
Intervention: Prolonged strenuous exercise (100-km ultramarathon)
Number of subjects: 10
Study: 9230234

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg b.i.d.) with budesonide (800 microg b.i.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salmeterol (50 microg b.i.d.) with placebo
Number of subjects: 18
Study: 8121125

Group type: EXPERIMENTAL
Intervention: Aspirin (165 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Heparin (1000 U/h)
Number of subjects: 51
Study: 3478465

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing 0.1% fluoride
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 2% citrate buffered dentifrice in a pluronic gel
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.1% fluoride and 2% citrate buffer in a pluronic gel
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 87
Study: 30482616

Group type: EXPERIMENTAL
Intervention: Tie over method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin stapler fixation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue fixation
Number of subjects: 0
Study: 27247448

Group type: EXPERIMENTAL
Intervention: Shielding drape
Number of subjects: 0

Group type: COMPARATOR
Intervention: No shielding drape (control)
Number of subjects: 0
Study: 25856785

Group type: EXPERIMENTAL
Intervention: ARB + Hydrochlorothiazide (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ARB + Amlodipine (ARB + C)
Number of subjects: 0
Study: 23350826

Group type: EXPERIMENTAL
Intervention: Internet-based treatment programme (124 women)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Postal treatment programme (126 women)
Number of subjects: 250
Study: 21295409

Group type: EXPERIMENTAL
Intervention: Ivermectin/pyrantel pamoate chewable tablets
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Milbemycin oxime flavored tablets
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Selamectin topical solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Imidacloprid/moxidectin topical solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 44